Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. (Q30374407)

21 June 2017

1 reference

title

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. (English)

1 reference

21 June 2017

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

6

Daniël H van Raalte

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

4

Mark H H Kramer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

3

Mark M Smits

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Lennart Tonneijck

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Hiddo J Lambers Heerspink

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

1 May 2015

1 reference

The Lancet: Diabetes & Endocrinology

21 June 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

367-381

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Diabetic kidney disease: act now or pay later

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Diabetic kidney disease: a report from an ADA Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The kidney in type 2 diabetes therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Surrogate end points for clinical trials of kidney disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Microalbuminuria: target for renoprotective therapy PRO.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Direct and indirect effects of obesity on the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Body mass index and risk for end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Metformin monotherapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effects of intensive blood-pressure control in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The effect of RAAS blockade on the progression of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

A meta-analysis of the effect of thiazolidinediones on blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The cardiovascular effects of the thiazolidinediones: a review of the clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Hemodynamically mediated glomerular injury and the progressive nature of kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Glomerular hyperfiltration: definitions, mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Renal hyperfiltration related to diabetes mellitus and obesity in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Glomerular hyperfiltration and renal disease progression in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The GFR and GFR decline cannot be accurately estimated in type 2 diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

How does proteinuria cause progressive renal damage?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Renal albumin absorption in physiology and pathology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Renal tubule albumin transport

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Corticosteroid therapy in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The end of dual therapy with renin-angiotensin-aldosterone system blockade?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The potential for renoprotection with incretin-based drugs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Statins for improving renal outcomes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Meta-analysis: the effect of statins on albuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Basal insulin and cardiovascular and other outcomes in dysglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Pioglitazone--do we really need it to manage type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Therapeutic approaches to diabetic nephropathy--beyond the RAS.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900030-3

7 January 2021

10.1016/S2213-8587(15)00030-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943756%20AND%20SRC:MED&resulttype=core&format=json

release_bvk27zfhgzgj3iknmavafmpiju

10 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bvk27zfhgzgj3iknmavafmpiju

24 November 2022

mapped directly with Wikidata item

1 reference